The publication of the EU’s first critical medicines list is a welcome development as it could inform discussions between industry and EU bodies about far reaching changes to the EU’s pharmaceutical legislation, according to Bengt Mattson, head of medicines supply at Lif, the Swedish pharmaceutical industry association.
However, he warns that forthcoming additional measures associated with the list, such as stockpiling and procurement requirements, could be counterproductive and says
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?